• Je něco špatně v tomto záznamu ?

The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma

V. Soukup, O. Capoun, M. Pesl, L. Vavrova, R. Sobotka, K. Levova, T. Hanus, T. Zima, M. Kalousova,

. 2019 ; 66 (6) : 1019-1023. [pub] 20191008

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044506

Aim of the study is to define the diagnostic accuracy of selected urinary protein biomarkers in the non-invasive detection of primary and recurrent urothelial carcinoma of the urinary bladder. The urinary levels of calprotectin, CD147, APOA4 and protein deglycase DJ-1 were examined in 255 individuals, including 60 controls with non-malignant urological disease, 61 patients with a history of urinary bladder cancer with negative cytology and negative cystoscopy and 134 patients with urinary bladder cancer. Urinary concentrations of biomarkers were determined by Enzyme-Linked Immunosorbent Assay (ELISA). During the follow-up of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared to the group of 61 patients with a history of NMIBC but with no evidence of disease. Urinary concentrations of the evaluated markers did not reveal any significant difference between these groups. During the primary diagnosis, a group of 90 patients with primary bladder cancer and 60 subjects with benign disease were compared. Urinary levels of CD147 were not significantly higher in patients with tumors. The greatest diagnostic accuracy was observed in APOA4 (sensitivity 55.6, specificity 83.3, AUC 0.75), and lesser in calprotectin (sensitivity 39.4, specificity 87.7, AUC 0.66) and in DJ-1 (sensitivity 61.1, specificity 66.7, AUC 0.64), respectively. Apolipoprotein A4 may be used potentially as a supplemental urinary marker in the diagnosis of primary bladder cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044506
003      
CZ-PrNML
005      
20220324093709.0
007      
ta
008      
200109s2019 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2019_190124N74 $2 doi
035    __
$a (PubMed)31607136
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Soukup, V $u Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
245    14
$a The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma / $c V. Soukup, O. Capoun, M. Pesl, L. Vavrova, R. Sobotka, K. Levova, T. Hanus, T. Zima, M. Kalousova,
520    9_
$a Aim of the study is to define the diagnostic accuracy of selected urinary protein biomarkers in the non-invasive detection of primary and recurrent urothelial carcinoma of the urinary bladder. The urinary levels of calprotectin, CD147, APOA4 and protein deglycase DJ-1 were examined in 255 individuals, including 60 controls with non-malignant urological disease, 61 patients with a history of urinary bladder cancer with negative cytology and negative cystoscopy and 134 patients with urinary bladder cancer. Urinary concentrations of biomarkers were determined by Enzyme-Linked Immunosorbent Assay (ELISA). During the follow-up of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared to the group of 61 patients with a history of NMIBC but with no evidence of disease. Urinary concentrations of the evaluated markers did not reveal any significant difference between these groups. During the primary diagnosis, a group of 90 patients with primary bladder cancer and 60 subjects with benign disease were compared. Urinary levels of CD147 were not significantly higher in patients with tumors. The greatest diagnostic accuracy was observed in APOA4 (sensitivity 55.6, specificity 83.3, AUC 0.75), and lesser in calprotectin (sensitivity 39.4, specificity 87.7, AUC 0.66) and in DJ-1 (sensitivity 61.1, specificity 66.7, AUC 0.64), respectively. Apolipoprotein A4 may be used potentially as a supplemental urinary marker in the diagnosis of primary bladder cancer.
650    _2
$a apolipoproteiny A $x moč $7 D001054
650    _2
$a basigin $x moč $7 D051926
650    _2
$a nádorové biomarkery $x moč $7 D014408
650    _2
$a lidé $7 D006801
650    _2
$a leukocytární L1-antigenní komplex $x moč $7 D039841
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a PARK7 $x moč $7 D000071617
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a nádory močového měchýře $x diagnóza $x moč $7 D001749
655    _2
$a časopisecké články $7 D016428
700    1_
$a Capoun, O $u Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Pesl, M $u Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Vavrova, L $u Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Sobotka, R $u Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Levová, Kateřina, $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $d 1985- $7 xx0271128
700    1_
$a Hanus, T $u Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Zima, T $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Kalousova, M $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 66, č. 6 (2019), s. 1019-1023
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31607136 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20220324093702 $b ABA008
999    __
$a ok $b bmc $g 1482775 $s 1083179
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 66 $c 6 $d 1019-1023 $e 20191008 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...